{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T17:14:57Z","timestamp":1790356497622,"version":"4.1.0"},"reference-count":32,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,10,23]],"date-time":"2025-10-23T00:00:00Z","timestamp":1761177600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100014337","name":"Menarini Group","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100014337","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Blood Neoplasia"],"published-print":{"date-parts":[[2026,2]]},"DOI":"10.1016\/j.bneo.2025.100178","type":"journal-article","created":{"date-parts":[[2025,10,25]],"date-time":"2025-10-25T07:30:01Z","timestamp":1761377401000},"page":"100178","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["Dual FLT3\/PIM inhibitor dapolsertib in acute myeloid leukemia: results from the phase 1\/2 DIAMOND-01 trial"],"prefix":"10.1016","volume":"3","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1025-4210","authenticated-orcid":false,"given":"Giovanni","family":"Martinelli","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scott R.","family":"Solomon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sudipto","family":"Mukherjee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Armando","family":"Santoro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6861-2041","authenticated-orcid":false,"given":"Stephen A.","family":"Strickland","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susana","family":"Vives","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Farhad","family":"Ravandi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9268-3341","authenticated-orcid":false,"given":"Roland B.","family":"Walter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachel J.","family":"Cook","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9592-0851","authenticated-orcid":false,"given":"Ewa","family":"Lech-Maranda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Calbacho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7909-457X","authenticated-orcid":false,"given":"Agnieszka","family":"Wierzbowska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6309-0515","authenticated-orcid":false,"given":"Giovanni","family":"Marconi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2869-369X","authenticated-orcid":false,"given":"Evelyn","family":"Acu\u00f1a-Cruz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-7129-8581","authenticated-orcid":false,"given":"Isabel","family":"Cano-Ferri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Bertolini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomasz","family":"Rzymski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1128-6839","authenticated-orcid":false,"given":"Alessandro","family":"Paoli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanni Marino","family":"Merlo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Faten Koraichi","family":"Auriol","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1240-8057","authenticated-orcid":false,"given":"Sonia","family":"Zicari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Galleu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ira","family":"Gupta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3275-5593","authenticated-orcid":false,"given":"Pau","family":"Montesinos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bneo.2025.100178_bib1","article-title":"Burden of AML, 1990-2019: estimates from the global burden of disease study","volume":"9","author":"Jani","year":"2023","journal-title":"JCO Glob Oncol"},{"issue":"22","key":"10.1016\/j.bneo.2025.100178_bib2","first-page":"2059","article-title":"Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia [published correction appears in N Engl J Med. 2013;369(1):98]","volume":"368","author":"Cancer Genome Atlas Research Network","year":"2013","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1016\/j.bneo.2025.100178_bib3","first-page":"6766","article-title":"Prognosis and outcome of patients with acute myeloid leukemia based on FLT3-ITD mutation with or without additional abnormal cytogenetics","volume":"18","author":"Tao","year":"2019","journal-title":"Oncol Lett"},{"issue":"3","key":"10.1016\/j.bneo.2025.100178_bib4","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1002\/ajh.26451","article-title":"Improved outcomes among newly diagnosed patients with FMS-like tyrosine kinase 3 internal tandem duplication mutated acute myeloid leukemia treated with contemporary therapy: revisiting the European LeukemiaNet adverse risk classification","volume":"97","author":"Reville","year":"2022","journal-title":"Am J Hematol"},{"issue":"10388","key":"10.1016\/j.bneo.2025.100178_bib5","doi-asserted-by":"crossref","first-page":"1571","DOI":"10.1016\/S0140-6736(23)00464-6","article-title":"Quizartinib plus chemotherapy in newly diagnosed patients with FLT3-internal-tandem-duplication-positive acute myeloid leukaemia (QuANTUM-First): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"401","author":"Erba","year":"2023","journal-title":"Lancet"},{"issue":"18","key":"10.1016\/j.bneo.2025.100178_bib6","doi-asserted-by":"crossref","first-page":"1728","DOI":"10.1056\/NEJMoa1902688","article-title":"Gilteritinib or chemotherapy for relapsed or refractory FLT3-mutated AML","volume":"381","author":"Perl","year":"2019","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1016\/j.bneo.2025.100178_bib7","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1056\/NEJMoa1614359","article-title":"Midostaurin plus chemotherapy for acute myeloid leukemia with a FLT3 mutation","volume":"377","author":"Stone","year":"2017","journal-title":"N Engl J Med"},{"issue":"23","key":"10.1016\/j.bneo.2025.100178_bib8","doi-asserted-by":"crossref","first-page":"3366","DOI":"10.1182\/blood.2021011583","article-title":"Follow-up of patients with R\/R FLT3-mutation-positive AML treated with gilteritinib in the phase 3 ADMIRAL trial","volume":"139","author":"Perl","year":"2022","journal-title":"Blood"},{"issue":"11","key":"10.1016\/j.bneo.2025.100178_bib9","doi-asserted-by":"crossref","first-page":"3647","DOI":"10.3390\/jcm12113647","article-title":"Gilteritinib: the story of a proceeding success into hard-to-treat FLT3-mutated AML patients","volume":"12","author":"Molica","year":"2023","journal-title":"J Clin Med"},{"issue":"1","key":"10.1016\/j.bneo.2025.100178_bib10","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1182\/blood-2016-04-711820","article-title":"Heterogeneous resistance to quizartinib in acute myeloid leukemia revealed by single-cell analysis","volume":"130","author":"Smith","year":"2017","journal-title":"Blood"},{"issue":"7","key":"10.1016\/j.bneo.2025.100178_bib11","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1016\/S1470-2045(19)30150-0","article-title":"Quizartinib versus salvage chemotherapy in relapsed or refractory FLT3-ITD acute myeloid leukaemia (QuANTUM-R): a multicentre, randomised, controlled, open-label, phase 3 trial [Erratum in: Lancet Oncol. 2019;20(7):e346]","volume":"20","author":"Cortes","year":"2019","journal-title":"Lancet Oncol"},{"issue":"5","key":"10.1016\/j.bneo.2025.100178_bib12","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1038\/s41408-022-00677-7","article-title":"Clinical outcomes in patients with relapsed\/refractory FLT3-mutated acute myeloid leukemia treated with gilteritinib who received prior midostaurin or sorafenib","volume":"12","author":"Perl","year":"2022","journal-title":"Blood Cancer J"},{"issue":"6","key":"10.1016\/j.bneo.2025.100178_bib13","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1182\/blood-2017-04-779405","article-title":"Enasidenib in mutant IDH2 relapsed or refractory acute myeloid leukemia","volume":"130","author":"Stein","year":"2017","journal-title":"Blood"},{"issue":"25","key":"10.1016\/j.bneo.2025.100178_bib14","doi-asserted-by":"crossref","first-page":"2386","DOI":"10.1056\/NEJMoa1716984","article-title":"Durable remissions with ivosidenib in IDH1-mutated relapsed or refractory AML","volume":"378","author":"DiNardo","year":"2018","journal-title":"N Engl J Med"},{"issue":"13","key":"10.1016\/j.bneo.2025.100178_bib15","doi-asserted-by":"crossref","first-page":"3117","DOI":"10.1182\/bloodadvances.2022009411","article-title":"Olutasidenib (FT-2102) induces durable complete remissions in patients with relapsed or refractory IDH1-mutated AML","volume":"7","author":"De Botton","year":"2023","journal-title":"Blood Adv"},{"issue":"1","key":"10.1016\/j.bneo.2025.100178_bib16","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1186\/s12943-023-01721-1","article-title":"Targeting Pim kinases in hematological cancers: molecular and clinical review","volume":"22","author":"Bellon","year":"2023","journal-title":"Mol Cancer"},{"issue":"8","key":"10.1016\/j.bneo.2025.100178_bib17","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.1500221","article-title":"Pim kinases modulate resistance to FLT3 tyrosine kinase inhibitors in FLT3-ITD acute myeloid leukemia","volume":"1","author":"Green","year":"2015","journal-title":"Sci Adv"},{"issue":"24","key":"10.1016\/j.bneo.2025.100178_bib18","doi-asserted-by":"crossref","first-page":"16917","DOI":"10.18632\/oncotarget.24747","article-title":"A novel, dual pan-PIM\/FLT3 inhibitor SEL24 exhibits broad therapeutic potential in acute myeloid leukemia","volume":"9","author":"Czardybon","year":"2018","journal-title":"Oncotarget"},{"issue":"1","key":"10.1016\/j.bneo.2025.100178_bib19","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1158\/1078-0432.CCR-17-1629","article-title":"Concurrent inhibition of Pim and FLT3 kinases enhances apoptosis of FLT3-ITD acute myeloid leukemia cells through increased Mcl-1 proteasomal degradation","volume":"24","author":"Kapoor","year":"2018","journal-title":"Clin Cancer Res"},{"issue":"7","key":"10.1016\/j.bneo.2025.100178_bib20","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1182\/bloodadvances.2018029850","article-title":"Hematopoietic cytokines mediate resistance to targeted therapy in FLT3-ITD acute myeloid leukemia","volume":"3","author":"Sung","year":"2019","journal-title":"Blood Adv"},{"issue":"4","key":"10.1016\/j.bneo.2025.100178_bib21","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1182\/blood-2016-08-733196","article-title":"Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel","volume":"129","author":"D\u00f6hner","year":"2017","journal-title":"Blood"},{"issue":"23","key":"10.1016\/j.bneo.2025.100178_bib22","doi-asserted-by":"crossref","first-page":"e70235","DOI":"10.1111\/jcmm.70235","article-title":"The dual PIM\/FLT3 inhibitor MEN1703 combines synergistically with gilteritinib in FLT3-ITD-mutant acute myeloid leukaemia","volume":"28","author":"Zicari","year":"2024","journal-title":"J Cell Mol Med"},{"issue":"1","key":"10.1016\/j.bneo.2025.100178_bib23","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/j.ccell.2022.12.002","article-title":"Modulation of RNA splicing enhances response to BCL2 inhibition in leukemia","volume":"41","author":"Wang","year":"2023","journal-title":"Cancer Cell"},{"issue":"5","key":"10.1016\/j.bneo.2025.100178_bib24","doi-asserted-by":"crossref","DOI":"10.1084\/jem.20200924","article-title":"Mitochondrial metabolism supports resistance to IDH mutant inhibitors in acute myeloid leukemia","volume":"218","author":"Stuani","year":"2021","journal-title":"J Exp Med"},{"key":"10.1016\/j.bneo.2025.100178_bib25","doi-asserted-by":"crossref","DOI":"10.1016\/j.bcp.2020.114253","article-title":"Targeting mitochondrial respiration for the treatment of acute myeloid leukemia","volume":"182","author":"Carter","year":"2020","journal-title":"Biochem Pharmacol"},{"issue":"12","key":"10.1016\/j.bneo.2025.100178_bib26","doi-asserted-by":"crossref","first-page":"2597","DOI":"10.1038\/s41388-020-1168-9","article-title":"PIM kinases alter mitochondrial dynamics and chemosensitivity in lung cancer","volume":"39","author":"Chauhan","year":"2020","journal-title":"Oncogene"},{"issue":"6","key":"10.1016\/j.bneo.2025.100178_bib27","doi-asserted-by":"crossref","first-page":"1004","DOI":"10.3324\/haematol.2009.017079","article-title":"PIM serine\/threonine kinases in the pathogenesis and therapy of hematologic malignancies and solid cancers","volume":"95","author":"Brault","year":"2010","journal-title":"Haematologica"},{"key":"10.1016\/j.bneo.2025.100178_bib28","article-title":"Exploiting the therapeutic vulnerability of IDH-mutant gliomas with zotiraciclib","author":"Pang","year":"2024","journal-title":"bioRxiv"},{"key":"10.1016\/j.bneo.2025.100178_bib29","author":"Tagliavini"},{"key":"10.1016\/j.bneo.2025.100178_bib30","doi-asserted-by":"crossref","DOI":"10.1016\/j.critrevonc.2024.104424","article-title":"Understanding mechanisms of resistance to FLT3 inhibitors in adult FLT3-mutated acute myeloid leukemia to guide treatment strategy","volume":"201","author":"Ruglioni","year":"2024","journal-title":"Crit Rev Oncol Hematol"},{"issue":"9","key":"10.1016\/j.bneo.2025.100178_bib31","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1080\/17474086.2021.1969911","article-title":"Safety of FLT3 inhibitors in patients with acute myeloid leukemia","volume":"14","author":"Cerchione","year":"2021","journal-title":"Expert Rev Hematol"},{"issue":"16","key":"10.1016\/j.bneo.2025.100178_bib32","doi-asserted-by":"crossref","first-page":"4280","DOI":"10.1158\/1078-0432.CCR-20-0834","article-title":"Differentiation syndrome with ivosidenib and enasidenib treatment in patients with relapsed or refractory IDH-mutated AML: a U.S. Food and Drug Administration systematic analysis","volume":"26","author":"Norsworthy","year":"2020","journal-title":"Clin Cancer Res"}],"container-title":["Blood Neoplasia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S295032802500113X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S295032802500113X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,2,19]],"date-time":"2026-02-19T01:48:03Z","timestamp":1771465683000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S295032802500113X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2]]},"references-count":32,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,2]]}},"alternative-id":["S295032802500113X"],"URL":"https:\/\/doi.org\/10.1016\/j.bneo.2025.100178","relation":{},"ISSN":["2950-3280"],"issn-type":[{"value":"2950-3280","type":"print"}],"subject":[],"published":{"date-parts":[[2026,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Dual FLT3\/PIM inhibitor dapolsertib in acute myeloid leukemia: results from the phase 1\/2 DIAMOND-01 trial","name":"articletitle","label":"Article Title"},{"value":"Blood Neoplasia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bneo.2025.100178","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 American Society of Hematology. Published by Elsevier Inc. Licensed under Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0), permitting only noncommercial, nonderivative use with attribution. All other rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"100178"}}